124 related articles for article (PubMed ID: 31740232)
1. Correlation between RICTOR overexpression and amplification in advanced solid tumors.
Bang H; Ahn S; Ji Kim E; Kim ST; Park HY; Lee J; Kim KM
Pathol Res Pract; 2020 Jan; 216(1):152734. PubMed ID: 31740232
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition.
Kim ST; Kim SY; Klempner SJ; Yoon J; Kim N; Ahn S; Bang H; Kim KM; Park W; Park SH; Park JO; Park YS; Lim HY; Lee SH; Park K; Kang WK; Lee J
Ann Oncol; 2017 Mar; 28(3):547-554. PubMed ID: 28028034
[TBL] [Abstract][Full Text] [Related]
3. Correlation between immunohistochemistry and RICTOR fluorescence in situ hybridization amplification in small cell lung carcinoma.
Krencz I; Sebestyen A; Papay J; Lou Y; Lutz GF; Majewicz TL; Khoor A
Hum Pathol; 2019 Nov; 93():74-80. PubMed ID: 31454632
[TBL] [Abstract][Full Text] [Related]
4.
Krencz I; Sztankovics D; Sebestyén A; Pápay J; Dankó T; Moldvai D; Lutz E; Khoor A
Pathol Oncol Res; 2024; 30():1611593. PubMed ID: 38706776
[No Abstract] [Full Text] [Related]
5. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
Morrison Joly M; Williams MM; Hicks DJ; Jones B; Sanchez V; Young CD; Sarbassov DD; Muller WJ; Brantley-Sieders D; Cook RS
Breast Cancer Res; 2017 Jun; 19(1):74. PubMed ID: 28666462
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction.
Kim MA; Jung EJ; Lee HS; Lee HE; Jeon YK; Yang HK; Kim WH
Hum Pathol; 2007 Sep; 38(9):1386-93. PubMed ID: 17555797
[TBL] [Abstract][Full Text] [Related]
7. Novel RICTOR amplification harbouring entities: FISH validation of RICTOR amplification in tumour tissue after next-generation sequencing.
Sztankovics D; Krencz I; Moldvai D; Dankó T; Nagy Á; Nagy N; Bedics G; Rókusz A; Papp G; Tőkés AM; Pápay J; Sápi Z; Dezső K; Bödör C; Sebestyén A
Sci Rep; 2023 Nov; 13(1):19610. PubMed ID: 37949943
[TBL] [Abstract][Full Text] [Related]
8. Protein overexpression and gene amplification of c-erbB-2 in breast carcinomas: a comparative study of immunohistochemistry and fluorescence in situ hybridization of formalin-fixed, paraffin-embedded tissues.
Kobayashi M; Ooi A; Oda Y; Nakanishi I
Hum Pathol; 2002 Jan; 33(1):21-8. PubMed ID: 11823970
[TBL] [Abstract][Full Text] [Related]
9. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?
Sauer T; Wiedswang G; Boudjema G; Christensen H; Karesen R
APMIS; 2003 Mar; 111(3):444-50. PubMed ID: 12752225
[TBL] [Abstract][Full Text] [Related]
10. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.
Yano T; Doi T; Ohtsu A; Boku N; Hashizume K; Nakanishi M; Ochiai A
Oncol Rep; 2006 Jan; 15(1):65-71. PubMed ID: 16328035
[TBL] [Abstract][Full Text] [Related]
11. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system.
Ciampa A; Xu B; Ayata G; Baiyee D; Wallace J; Wertheimer M; Edmiston K; Khan A
Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):132-7. PubMed ID: 16785779
[TBL] [Abstract][Full Text] [Related]
12. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.
Hammock L; Lewis M; Phillips C; Cohen C
Hum Pathol; 2003 Oct; 34(10):1043-7. PubMed ID: 14608539
[TBL] [Abstract][Full Text] [Related]
13. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
[TBL] [Abstract][Full Text] [Related]
14. HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients.
Liu W; Zhong S; Chen J; Yu Y
J Clin Gastroenterol; 2012 Apr; 46(4):e31-7. PubMed ID: 22064554
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor overexpression/amplification in adenocarcinomas arising in the gastrointestinal tract.
Rossi E; Villanacci V; Danesino C; Donato F; Nascimbeni R; Bassotti G
Rev Esp Enferm Dig; 2011 Dec; 103(12):632-9. PubMed ID: 22217347
[TBL] [Abstract][Full Text] [Related]
16.
Kim LC; Rhee CH; Chen J
Mol Cancer Res; 2020 Nov; 18(11):1675-1684. PubMed ID: 32801163
[TBL] [Abstract][Full Text] [Related]
17. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.
Pauletti G; Dandekar S; Rong H; Ramos L; Peng H; Seshadri R; Slamon DJ
J Clin Oncol; 2000 Nov; 18(21):3651-64. PubMed ID: 11054438
[TBL] [Abstract][Full Text] [Related]
18. [HER2 gene amplification and overexpression in advanced gastric cancer].
Roa I; Slater J; Carvajal D; Schalper K; de Toro G; Ares R; Game A; León J; de Aretxabala X
Rev Med Chil; 2013 Nov; 141(11):1411-9. PubMed ID: 24718467
[TBL] [Abstract][Full Text] [Related]
19. RICTOR gene amplification is correlated with metastasis and therapeutic resistance in triple-negative breast cancer.
El Shamieh S; Saleh F; Moussa S; Kattan J; Farhat F
Pharmacogenomics; 2018 Jun; 19(9):757-760. PubMed ID: 29790419
[TBL] [Abstract][Full Text] [Related]
20. TELO2 induced progression of colorectal cancer by binding with RICTOR through mTORC2.
Guo Z; Zhang X; Zhu H; Zhong N; Luo X; Zhang Y; Tu F; Zhong J; Wang X; He J; Huang L
Oncol Rep; 2021 Feb; 45(2):523-534. PubMed ID: 33416177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]